14 results on '"Rosti, Giovanni"'
Search Results
2. Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies
- Author
-
Petrelli, Fausto, Coinu, Andrea, Rosti, Giovanni, Pedrazzoli, Paolo, and Barni, Sandro
- Published
- 2017
- Full Text
- View/download PDF
3. Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.
- Author
-
Bleve, Sara, Cursano, Maria Concetta, Casadei, Chiara, Schepisi, Giuseppe, Menna, Cecilia, Urbini, Milena, Gianni, Caterina, De Padova, Silvia, Filograna, Alessia, Gallà, Valentina, Rosti, Giovanni, Barone, Domenico, Chovanec, Michal, Mego, Michal, and De Giorgi, Ugo
- Subjects
TESTICULAR cancer ,METASTASIS ,GERM cell tumors ,DISEASE relapse ,PROGNOSIS ,THERAPEUTICS - Abstract
Germ cell tumors are the most common malignant tumors in male young adults. Platinum-based chemotherapy has dramatically improved the outcome of metastatic germ cell tumor patients and overall cure rates now exceed 80%. The choice of medical treatment can be guided by the prognosis estimation which is an important step during the decision-making process. IGCCCG classification plays a pivotal role in the management of advanced disease. However, histological and clinical parameters are the available factors that condition the prognosis, but they do not reflect the tumor's molecular and pathological features and do not predict who will respond to chemotherapy. After first-line chemotherapy 20%-30% of patients relapse and for these patients, the issue of prognostic factors is far more complex. Validated biomarkers and a molecular selection of patients that reflect the pathogenesis are highly needed. The association between cancer-related systemic inflammation, tumorigenesis, and cancer progression has been demonstrated. In the last years, several studies have shown the prognostic utility of immune-inflammation indexes in different tumor types. This review analyzed the prognostic impact of inflammatory markers retrieved from routine blood draws in GCT patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer
- Author
-
Scagliotti, Giorgio Vittorio, Ricardi, Umberto, Crinó, Lucio, Maranzano, Ernesto, Marinis, Filippo De, Morandi, Maria Grazia, Meacci, Luisa, Marangolo, Maurizio, Emiliani, Ermanno, Rosti, Giovanni, Figoli, Franco, Bolzicco, Gianfranco, Masiero, Paolo, Gentile, Alfonso, and Tonato, Maurizio
- Published
- 1996
- Full Text
- View/download PDF
5. Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress.
- Author
-
De Padova, Silvia, Urbini, Milena, Schepisi, Giuseppe, Virga, Alessandra, Meggiolaro, Elena, Rossi, Lorena, Fabbri, Francesco, Bertelli, Tatiana, Ulivi, Paola, Ruffilli, Federica, Casadei, Chiara, Gurioli, Giorgia, Rosti, Giovanni, Grassi, Luigi, and De Giorgi, Ugo
- Subjects
PSYCHOTHERAPY ,IMMUNOSENESCENCE ,PSYCHOLOGICAL distress ,TESTICULAR cancer ,CANCER survivors ,PSYCHONEUROIMMUNOLOGY - Abstract
Testicular cancer (TC) is the most frequent solid tumor diagnosed in young adult males. Although it is a curable tumor, it is frequently associated with considerable short-term and long-term morbidity. Both biological and psychological stress experienced during cancer therapy may be responsible for stimulating molecular processes that induce premature aging and deterioration of immune system (immunosenescence) in TC survivors, leading to an increased susceptibility to infections, cancer, and autoimmune diseases. Immunosenescence is a remodeling of immune cell populations with inversion of the CD4:CD8 ratio, accumulation of highly differentiated memory cells, shrinkage of telomeres, shift of T-cell response to Th2 type, and release of pro-inflammatory signals. TC survivors exposed to chemotherapy show features of immunological aging, including an increase in memory T-cells (CD4+ and CD8+) and high expression of the senescence biomarker p16INK4a in CD3+ lymphocytes. However, the plethora of factors involved in the premature aging of TC survivors make the situation more complex if we also take into account the psychological stress and hormonal changes experienced by patients, as well as the high-dose chemotherapy and hematopoietic stem cell transplantation that some individuals may be required to undergo. The relatively young age and the long life expectancy of TC patients bear witness to the importance of improving quality of life and of alleviating long-term side-effects of cancer treatments. Within this context, the present review takes an in-depth look at the molecular mechanisms of immunosenescence, describing experimental evidence of cancer survivor aging and highlighting the interconnected relationship between the many factors modulating the aging of the immune system of TC survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.
- Author
-
Casadei, Chiara, Schepisi, Giuseppe, Menna, Cecilia, Chovanec, Michal, Gurioli, Giorgia, Gallà, Valentina, Altavilla, Amelia, Marcellini, Massimo, Bellia, Salvatore Roberto, Lolli, Cristian, Mego, Michal, Rosti, Giovanni, and De Giorgi, Ugo
- Abstract
Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study
- Author
-
Jacques-Olivier, Bay, Bay, Jacques-Olivier, Claude, Linassier, Linassier, Claude, Pierre, Biron, Biron, Pierre, Xavier, Durando, Durando, Xavier, Pierre, Verrelle, Verrelle, Pierre, Fabrice, Kwiatkowski, Kwiatkowski, Fabrice, Giovanni, Rosti, Rosti, Giovanni, Taner, Demirer, and Demirer, Taner
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Autologous Stem Cell Rescue ,Adolescent ,medicine.medical_treatment ,Oligodendroglioma ,Transplantation, Autologous ,Autologous stem-cell transplantation ,Glioma ,medicine ,Humans ,Antineoplastic Agents, Alkylating ,Aged ,Retrospective Studies ,Chemotherapy ,Carmustine ,Temozolomide ,business.industry ,Hematopoietic Stem Cell Transplantation ,Supratentorial Neoplasms ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Surgery ,Transplantation ,Survival Rate ,Oncology ,Concomitant ,Female ,business ,Glioblastoma ,medicine.drug - Abstract
Radiotherapy plus concomitant and adjuvant temozolomide have demonstrated improved survival for glioblastoma. However, prognosis remains poor. High-doses chemotherapy with carmustine is another way to improve response and survival by increasing the dose delivered. Myelotoxicity imposes autologous stem cell rescue. European Group for Blood and Marrow Transplantation experience of this treatment in patients with high-grade glioma was reported here. A retrospective analysis of 217 patients from European Group for Blood and Marrow Transplantation database was realized. Ninety-six patients underwent complete surgical resection while the 121 others had partial resection or only biopsy and were evaluable for an antitumor effect. Patients received 800 mg/ m 2 of carmustine intravenously at least 1 month after neurosurgery. Forty-eight to 72 hr after chemotherapy, 108 patients received autologous hematopoietic stem cells from bone marrow harvest and 109 patients autologous hematopoietic stem cells from peripheral blood. Radiotherapy was started approximately 40 days after transplantation. Ten deaths were related to the treatment. Of the 121 patients evaluable for tumor response, 64 (53%) presented an objective response. This protocol appear feasible, but with toxicity-related mortality of 4.5%. Median overall survival was 20 months and median time to treatment failure was 7 months. Overall survival and time to treatment were correlated with age, quality of resection and histological subtypes. In glioblastoma multiforme, age and surgery quality appeared to be prognostic factors. Compared with Stupp et al.’s recent study, this study did not favor high-dose carmustine for patients with glioblastoma multiforme with complete surgical resection. ' 2007 Wiley-Liss, Inc.
- Published
- 2007
8. Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia.
- Author
-
Pedrazzoli, Paolo, Rosti, Giovanni, Secondino, Simona, and Siena, Salvatore
- Subjects
- *
ANEMIA treatment , *DIETARY supplements , *IRON in the body , *CANCER , *ONCOLOGY - Abstract
The article discusses the role of iron supplementation during treatment of chemotherapy-related anemia (CRA). The authors review several published reports that have addressed the issue. They conclude that iron supplementation, alone or in conjunction with erythropoiesis-stimulatory agents (ESA) is a valid therapeutic tool for the treatment of cancer anemia and its use should be considered in medical oncology.
- Published
- 2009
- Full Text
- View/download PDF
9. Prevention and therapy of neutropenia in elderly patients
- Author
-
Rosti, Giovanni, Kopf, Barbara, Cariello, Anna, Monti, Manlio, Dazzi, Claudio, Papiani, Giorgio, Giovanis, Petros, De Giorgi, Ugo, and Marangolo, Maurizio
- Subjects
- *
NEUTROPENIA , *DRUG therapy , *THERAPEUTICS - Abstract
Standard chemotherapy in elderly patients is still nowadays a difficult issue, due to the fact that marrow reserve decrease with age and the results might lead to higher toxicity of otherwise well tolerated regimen and schedule. In the literature, very few data exist of myelosuppression in patients with solid tumors, while more data have been published on non-Hodgkin''s lymphoma. The burden of toxicity increase with age, leading to the fact that some patients with curable or sensitive disease do not receive appropriate treatment. One of the ways to try to circumvent neutropenia is the prophylactic use of haematopoietic growth factors with the double aim of maintaining dose-intensity and reducing toxicity. This paper will describe the patterns of marrow toxicity in treating elderly patients with cancer and the role of haematopoietic growth factors. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
10. Sequential adjuvant chemotherapy for patients with high-risk urinary tract carcinomas: a retrospective analysis of a patient's series.
- Author
-
Zustovich, Fable, Farina, Patrizia, Amirouchene, Nabil, Carli, Paolo, Rosti, Giovanni, Lombardi, Giuseppe, and Cartei, Giuseppe
- Subjects
- *
URINARY organ cancer , *CANCER chemotherapy , *ADJUVANT treatment of cancer , *ONCOLOGIC surgery , *CARBOPLATIN , *VINORELBINE , *REDUCTION of drug dosage - Abstract
Aims and Background: there is no evidence of benefit for adjuvant chemotherapy in high-risk patients with urothelial carcinomas; to improve results of surgery we treated a series of patients with a multi-drug sequential chemotherapy protocol. Methods: patients with G3 or pT3 or pN+ urinary tract carcinomas were treated with 3 courses of carboplatin plus gemcitabine every 21 days followed by 3 courses of paclitaxel, vinorelbine and methotrexate every 21 days. Results: 21 patients were enrolled, all patients were evaluable for toxicity that was manageable and mostly haematological grade 1-2, 9 patients needed some dose reduction. The median disease-free survival (DFS) was of 21.8 months (4.3-48.7+) and median overall survival (OS) was of 25.4 months (9-51.4). Conclusions: carboplatin and gemcitabine followed by paclitaxel, vinorelbine and methotrexate is feasible and safe and might deserve to be studied in a fase III trial of adjuvant chemotherapy for patients with high-risk urothelial carcinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2011
11. High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry
- Author
-
Andrea Ravelli, Alberto Bosi, Paolo Pedrazzoli, Manuela Badoglio, Carmelo Bengala, Andrea Necchi, Marco Bregni, Ruben Leno Nunez, Mustafa Ozturk, Francesco Lanza, Didier Blaise, Lorenzo Pavesi, Giovanni Rosti, Daniele Generali, Massimo Martino, Ugo De Giorgi, Hendricus Schouten, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Martino, Massimo, Lanza, Francesco, Pavesi, Lorenzo, Öztürk, Mustafa, Blaise, Didier, Leno Núñez, Rubén, Schouten, Harry C., Bosi, Alberto, De Giorgi, Ugo, Generali, Daniele, Rosti, Giovanni, Necchi, Andrea, Ravelli, Andrea, Bengala, Carmelo, Badoglio, Manuela, Pedrazzoli, Paolo, Bregni, Marco, Martino, M, Lanza, F, Pavesi, L, Ozturk, M, Blaise, D, Nunez, Rl, Schouten, Hc, Bosi, A, De Giorgi, U, Generali, D, Rosti, G, Necchi, A, Ravelli, A, Bengala, C, Badoglio, M, Pedrazzoli, P, and Bregni, M
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,High-risk breast cancer ,medicine.medical_treatment ,Population ,Breast Neoplasms ,Hematopoietic stem cell transplantation ,Disease-Free Survival ,NO ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,High-dose chemotherapy ,medicine ,Chemotherapy ,Humans ,Registries ,Autografts ,education ,Survival rate ,Adjuvant ,Aged ,Transplantation ,education.field_of_study ,Hematology ,business.industry ,Mortality rate ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,medicine.disease ,Autologous hematopoietic stem cell transplantation ,Surgery ,Europe ,Survival Rate ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology - Abstract
The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had >= 10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9% between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors
- Published
- 2016
12. Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: A 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Patrizia Giannatempo, Paolo Pedrazzoli, Christian Chabannon, Lo Vullo S, Andrea Necchi, S. Secondino, Manuela Badoglio, Luigi Mariani, Francesco Lanza, Daniele Raggi, Chiara Bonini, Giovanni Rosti, Necchi, Andrea, Lo Vullo, Salvatore, Secondino, Simona, Rosti, Giovanni, Badoglio, Manuela, Giannatempo, Patrizia, Raggi, Daniele, Lanza, Francesco, Chabannon, Christian, Bonini, Chiara, Mariani, Luigi, and Pedrazzoli, Paolo
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,NO ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Humans ,Cumulative incidence ,Young adult ,Etoposide ,Testicular cancer ,Retrospective Studies ,Transplantation ,Chemotherapy ,Europe ,Female ,Neoplasms, Germ Cell and Embryonal ,Neoplasms, Second Primary ,business.industry ,Incidence (epidemiology) ,Retrospective cohort study ,Hematology ,medicine.disease ,030104 developmental biology ,Second Primary ,030220 oncology & carcinogenesis ,Germ Cell and Embryonal ,Germ cell tumors ,business ,medicine.drug - Abstract
We aimed to assess the incidence and risk factors of secondary malignancy (SM) in the young adult patients who received high-dose chemotherapy (HDCT) for germ cell tumors (GCT). The EBMT database was interrogated. Criteria for patient selection included adult male GCT and HDCT administered in any line of therapy. Cumulative incidence methods were used to estimate the time-to-SM diagnosis. Univariable Fine and Gray proportional hazard regression evaluated risk factors of SM occurrence. From 1981 to 2015, 9153 autografts were identified. Among 5295 patients, 59 cases of SM, developed after a median follow-up of 3.8 years, were registered. Of these patients, 23 (39%) developed hematologic SM, 34 (57.6%) solid SM (two patients had uncoded SM). Twenty-year cumulative incidence of solid versus hematologic SM was 4.17% (95% CI: 1.78-6.57) versus 1.37% (95% CI: 0.47-2.27). Median overall survival after SM was significantly shorter for patients who developed hematologic SM versus solid SM (8.6 versus 34.4 months, p = 0.003). Age older than 40 years at the time of HDCT was significantly associated with hematologic, but not solid, SM development (p = 0.004 versus p = 0.234). SM occurrence post-HDCT showed different patterns of incidence and mortality in GCT. These data may be important to optimize patient selection, counseling and follow-up after HDCT.
- Published
- 2018
13. Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours
- Author
-
Nicoletta De Luigi, Giovanni Rosti, Roberto Corsi, Andrea Casadei Gardini, Cecilia Menna, Giorgio Papiani, Salvatore Luca Burgio, Luca Burgio, Salvatore, Menna, Cecilia, Papiani, Giorgio, Casadei Gardini, Andrea, De Luigi, Nicoletta, Corsi, Roberto, and Rosti, Giovanni
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Pathology ,Alpha-fetoprotein levels ,Germ cell tumour ,High-dose chemotherapy ,Progressive disease ,Residual mass ,Pharmacology ,Pharmacology (medical) ,Infectious Diseases ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,Biology ,Mediastinal Neoplasms ,High dose chemotherapy ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Standard treatment ,Induction chemotherapy ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,medicine.anatomical_structure ,alpha-Fetoproteins ,Chemical and Drug Induced Liver Injury ,Alpha-fetoprotein ,Germ cell - Abstract
In patients with non-seminomatous germ cell tumours (NSGCTs) who receive chemotherapy and have residual disease, a persistently elevated serum marker level after induction chemotherapy indicates active and progressive disease. High-dose chemotherapy (HDCT) is the standard treatment for patients with relapsed NSGCT. We present a case of a patient with residual disease from NSGCT who showed an increase in serum alpha-fetoprotein levels after HDCT, mimicking progression. Resection of the mass did not show viable cells in the tumour specimen, thus suggesting that the elevated level of the marker was expression of hepatic reconstitution after drug-induced liver damage. HDCT is increasingly used in cases of relapsed NSGCT, and the possibility of treatment-induced alpha-fetoprotein elevation must be taken into account in patient management. © 2013 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia.
- Published
- 2013
14. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
- Author
-
Sandro Barni, Simona Secondino, Francesco Lanza, Giovanni Rosti, Daniele Generali, Massimo Martino, Paolo Pedrazzoli, Alberto Bottini, Luca Castagna, Roberto Maisano, Martino, Massimo, Bottini, Alberto, Rosti, Giovanni, Generali, Daniele, Secondino, Simona, Barni, Sandro, Maisano, Roberto, Lanza, Francesco, Castagna, Luca, and Pedrazzoli, Paolo
- Subjects
Oncology ,medicine.medical_treatment ,High-risk breast cancer ,Clinical Biochemistry ,autologous transplantation ,Antineoplastic Agent ,high-risk breast cancer ,High dose chemotherapy ,stem cell mobilization and collection ,Autologous hematopoietic progenitor cell transplantation ,High-dose chemotherapy ,Metastatic breast cancer ,Animals ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Combined Modality Therapy ,Disease-Free Survival ,Dose-Response Relationship, Drug ,Female ,Hematopoietic Stem Cell Transplantation ,Humans ,Randomized Controlled Trials as Topic ,Transplantation, Autologous ,Pharmacology ,Drug Discovery3003 Pharmaceutical Science ,Medicine (all) ,Drug Discovery ,Transplantation, Autologou ,metastatic breast cancer ,Drug ,Autologous ,Breast Neoplasm ,Human ,medicine.medical_specialty ,NO ,Dose-Response Relationship ,Breast cancer ,Cell transplantation ,Internal medicine ,medicine ,Overall survival ,Chemotherapy ,Transplantation ,autologous hematopoietic progenitor cell transplantation ,Antineoplastic Combined Chemotherapy Protocol ,autologous hematopoietic progenitor cell transplantation, high-dose chemotherapy, high-risk breast cancer, metastatic breast cancer, stem cell mobilization and collection, autologous transplantation ,business.industry ,Animal ,medicine.disease ,Clinical trial ,Hematopoietic progenitor ,business ,high-dose chemotherapy - Abstract
INTRODUCTION: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. AREAS COVERED: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. EXPERT OPINION: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.